Ming-Juan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ming-Juan Chen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Heng Luo
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, China
1 shared publication - Jia-Hui Li
State Key Laboratory of Discovery and Utilization of Functiona Components in Traditional Chinese Medicine, Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550014, China
1 shared publication - Li-Rong Huang
College of Food and Pharmaceutical Engineering, Guizhou Institute of Technology, Guiyang 550025, China
1 shared publication - Qin-Qin Xiong
State Key Laboratory of Discovery and Utilization of Functiona Components in Traditional Chinese Medicine, Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550014, China
1 shared publication - Sha Cheng
State Key Laboratory of Discovery and Utilization of Functiona Components in Traditional Chinese Medicine, Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550014, China
1 shared publication - Ting Ye
State Key Laboratory of Discovery and Utilization of Functiona Components in Traditional Chinese Medicine, Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550014, China
1 shared publication
Latest Publications
- Open Access
Small-Leaved Kuding Tea Extract Fractions Attenuate Hyperlipidemia and Hepatic Steatosis in Mice: Association with Upregulation of Fatty Acid β-Oxidation Enzymes and Improvement of Metabolic Biomarkers
Background/Objectives: Hyperlipidemia is a prevalent metabolic disorder that increases cardiovascular disease risk and is associated with lipid accumulation, inflammation, and oxidative stress. Small-leaved Kuding tea (SLKT) has multiple health benefits, but its lipid-lowering mechanisms remain unclear. This study evaluated the therapeutic effects of different SLKT fractions on hyperlipidemia and investigated their modulation of the fatty acid degradation pathway. Methods: A hyperlipidemia mouse model was established using a high-fat diet for 8 weeks. Sixty successfully modeled mice were randomly divided into six groups: model control, anhydrous ethanol fraction (SLK-AE), ethyl acetate fraction (SLK-EA), n-butanol fraction (SLK-NA), water-soluble fraction (SLK-WA), and simvastatin (positive control). Mice received daily gavage for 8 weeks. Serum biochemical indices, inflammatory factors, hepatic oxidative stress markers, and liver histopathology were assessed. Protein expression levels of ACADM, EHHADH, and HADHB in the liver were detected by Western blot. Results: SLKT fractions significantly reduced body weight, fat mass, serum TC, TG, LDL-C, Glu, NEFA, ALT, AST, TNF-α, IL-1β, IL-6, and LPS, while increasing HDL-C (p < 0.05). Hepatic TC, TG, ALT, AST, and MDA decreased, and SOD increased (p < 0.05). Histological staining revealed markedly reduced lipid droplets in hepatocytes. Furthermore, SLKT significantly upregulated hepatic protein expression of ACADM, EHHADH, and HADHB, key enzymes in fatty acid β-oxidation (p < 0.05). Conclusions: SLKT effectively ameliorates hyperlipidemia by improving lipid profiles, reducing serum biomarkers of liver injury and pro-inflammatory cytokines, and upregulating key fatty acid degradation enzymes. These findings support SLKT as a potential natural therapeutic agent for hyperlipidemia and associated metabolic disorders.
Open AccessSmall-Leaved Kuding Tea Extract Fractions Attenuate Hyperlipidemia and Hepatic Steatosis in Mice: Association with Upregulation of Fatty Acid β-Oxidation Enzymes and Improvement of Metabolic Biomarkers
Background/Objectives: Hyperlipidemia is a prevalent metabolic disorder that increases cardiovascular disease risk and is associated with lipid accumulation, inflammation, and oxidative stress. Small-leaved Kuding tea (SLKT) has multiple health benefits, but its lipid-lowering mechanisms remain unclear. This study evaluated the therapeutic effects of different SLKT fractions on hyperlipidemia and investigated their modulation of the fatty acid degradation pathway. Methods: A hyperlipidemia mouse model was established using a high-fat diet for 8 weeks. Sixty successfully modeled mice were randomly divided into six groups: model control, anhydrous ethanol fraction (SLK-AE), ethyl acetate fraction (SLK-EA), n-butanol fraction (SLK-NA), water-soluble fraction (SLK-WA), and simvastatin (positive control). Mice received daily gavage for 8 weeks. Serum biochemical indices, inflammatory factors, hepatic oxidative stress markers, and liver histopathology were assessed. Protein expression levels of ACADM, EHHADH, and HADHB in the liver were detected by Western blot. Results: SLKT fractions significantly reduced body weight, fat mass, serum TC, TG, LDL-C, Glu, NEFA, ALT, AST, TNF-α, IL-1β, IL-6, and LPS, while increasing HDL-C (p < 0.05). Hepatic TC, TG, ALT, AST, and MDA decreased, and SOD increased (p < 0.05). Histological staining revealed markedly reduced lipid droplets in hepatocytes. Furthermore, SLKT significantly upregulated hepatic protein expression of ACADM, EHHADH, and HADHB, key enzymes in fatty acid β-oxidation (p < 0.05). Conclusions: SLKT effectively ameliorates hyperlipidemia by improving lipid profiles, reducing serum biomarkers of liver injury and pro-inflammatory cytokines, and upregulating key fatty acid degradation enzymes. These findings support SLKT as a potential natural therapeutic agent for hyperlipidemia and associated metabolic disorders.